348 related articles for article (PubMed ID: 26926107)
61. Elf5 inhibits TGF-β-driven epithelial-mesenchymal transition in prostate cancer by repressing SMAD3 activation.
Yao B; Zhao J; Li Y; Li H; Hu Z; Pan P; Zhang Y; Du E; Liu R; Xu Y
Prostate; 2015 Jun; 75(8):872-82. PubMed ID: 25728398
[TBL] [Abstract][Full Text] [Related]
62. [In vitro study of TGF-β1-induced epithelial-mesenchymal transition of keloid epithelial cells].
Yan L; Cao R; Pan B; Wang L; Lyu X; Sun X; Xiao R
Zhonghua Zheng Xing Wai Ke Za Zhi; 2015 Mar; 31(2):128-33. PubMed ID: 26211188
[TBL] [Abstract][Full Text] [Related]
63. Novel signaling collaboration between TGF-β and adaptor protein Crk facilitates EMT in human lung cancer.
Elmansuri AZ; Tanino MA; Mahabir R; Wang L; Kimura T; Nishihara H; Kinoshita I; Dosaka-Akita H; Tsuda M; Tanaka S
Oncotarget; 2016 May; 7(19):27094-107. PubMed ID: 27027347
[TBL] [Abstract][Full Text] [Related]
64. Luteolin attenuates TGF-β1-induced epithelial-mesenchymal transition of lung cancer cells by interfering in the PI3K/Akt-NF-κB-Snail pathway.
Chen KC; Chen CY; Lin CR; Yang TY; Chen TH; Wu LC; Wu CC
Life Sci; 2013 Dec; 93(24):924-33. PubMed ID: 24140887
[TBL] [Abstract][Full Text] [Related]
65. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
[TBL] [Abstract][Full Text] [Related]
66. Epithelial-mesenchymal transition and its transcription factors.
Debnath P; Huirem RS; Dutta P; Palchaudhuri S
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34708244
[TBL] [Abstract][Full Text] [Related]
67. Switch of ELF3 and ATF4 transcriptional axis programs the amino acid insufficiency-linked epithelial-to-mesenchymal transition.
Lin J; Hou L; Zhao X; Zhong J; Lv Y; Jiang X; Ye B; Qiao Y
Mol Ther; 2024 Jun; 32(6):1956-1969. PubMed ID: 38627967
[TBL] [Abstract][Full Text] [Related]
68. ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1.
Liu D; Skomorovska Y; Song J; Bowler E; Harris R; Ravasz M; Bai S; Ayati M; Tamai K; Koyuturk M; Yuan X; Wang Z; Wang Y; Ewing RM
Cancer Biol Ther; 2019; 20(1):90-100. PubMed ID: 30148686
[No Abstract] [Full Text] [Related]
69. Molecular dissection of the oncogenic role of ETS1 in the mesenchymal subtypes of head and neck squamous cell carcinoma.
Gluck C; Glathar A; Tsompana M; Nowak N; Garrett-Sinha LA; Buck MJ; Sinha S
PLoS Genet; 2019 Jul; 15(7):e1008250. PubMed ID: 31306413
[TBL] [Abstract][Full Text] [Related]
70. An integrated expression profiling reveals target genes of TGF-β and TNF-α possibly mediated by microRNAs in lung cancer cells.
Saito A; Suzuki HI; Horie M; Ohshima M; Morishita Y; Abiko Y; Nagase T
PLoS One; 2013; 8(2):e56587. PubMed ID: 23437179
[TBL] [Abstract][Full Text] [Related]
71. HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.
Pantelaiou-Prokaki G; Mieczkowska I; Schmidt GE; Fritzsche S; Prokakis E; Gallwas J; Wegwitz F
Clin Epigenetics; 2022 Jan; 14(1):7. PubMed ID: 35016723
[TBL] [Abstract][Full Text] [Related]
72. Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma.
Shi Y; Wu H; Zhang M; Ding L; Meng F; Fan X
Diagn Pathol; 2013 May; 8():89. PubMed ID: 23706092
[TBL] [Abstract][Full Text] [Related]
73. DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition.
Chen N; Balasenthil S; Reuther J; Frayna A; Wang Y; Chandler DS; Abruzzo LV; Rashid A; Rodriguez J; Lozano G; Cao Y; Lokken E; Chen J; Frazier ML; Sahin AA; Wistuba II; Sen S; Lott ST; Killary AM
Cancer Discov; 2013 Oct; 3(10):1172-89. PubMed ID: 23838884
[TBL] [Abstract][Full Text] [Related]
74. BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.
Andrieu GP; Denis GV
Mol Cancer Res; 2018 Apr; 16(4):580-586. PubMed ID: 29437854
[TBL] [Abstract][Full Text] [Related]
75. SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma.
Hsiao YJ; Su KY; Hsu YC; Chang GC; Chen JS; Chen HY; Hong QS; Hsu SC; Kang PH; Hsu CY; Ho BC; Yang TH; Wang CY; Jou YS; Yang PC; Yu SL
Oncotarget; 2016 Jul; 7(28):44417-44429. PubMed ID: 27323831
[TBL] [Abstract][Full Text] [Related]
76. Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma.
Song J; Wang W; Wang Y; Qin Y; Wang Y; Zhou J; Wang X; Zhang Y; Wang Q
BMC Cancer; 2019 Jul; 19(1):680. PubMed ID: 31296175
[TBL] [Abstract][Full Text] [Related]
77. NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation.
Chen PM; Wu TC; Cheng YW; Chen CY; Lee H
Oncotarget; 2015 Jun; 6(16):14274-89. PubMed ID: 25881545
[TBL] [Abstract][Full Text] [Related]
78. Whole DNA methylome profiling in lung cancer cells before and after epithelial-to-mesenchymal transition.
Liu F; Zhou Y; Zhou D; Kan M; Niu X; Zhang Z; Zhang D; Tao L; He L; Zhan L; Liu Y
Diagn Pathol; 2014 Mar; 9():66. PubMed ID: 24655585
[TBL] [Abstract][Full Text] [Related]
79. Caveolae as a target to quench autoinduction of the metastatic phenotype in lung cancer.
Garnett DJ
J Cancer Res Clin Oncol; 2016 Mar; 142(3):611-8. PubMed ID: 26573510
[TBL] [Abstract][Full Text] [Related]
80. Epithelial-mesenchymal transition promotes reactivity of human lung adenocarcinoma A549 cells to CpG ODN.
Kobayashi K; Koyama K; Suzukawa M; Igarashi S; Hebisawa A; Nagase T; Ohta K
Allergol Int; 2016 Sep; 65 Suppl():S45-52. PubMed ID: 27475623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
